PRP Study for Erectile Dysfunction

-Erectile dysfunction (ED) is a condition that is not limited to older men, ‘About 5 percent of men that are 40 years old have complete erectile dysfunction, and that number increases to about 15 percent of men at age 70. Mild and moderate erectile dysfunction affects approximately 10 percent of men per decade of life.’

While platelet-rich plasma (PRP) is not new to medicine, there has been limited clinical data for its application in the field of sexual medicine, specifically in conjunction with other forms of ED therapy. That is why expert physicians, including Joseph Banno, MD, Paul Perito, MD, Gabriel Antonini MD, and Lisbeth Roy DO, collaborated to provide a clinical study on the benefits of using PRP to treat ED. This abstract study provides an early review of PRP outcomes for ED.

During a 12-month period lasting from August 2015 and ending August 2016, patients at Midwest Urological Group incorporated PRP to a medication and vacuum therapy regimen. Patients with active/metastatic cancer or any blood dyscrasias were excluded. The PRP treatment used the patient’s own plasma and was administered once to each patient.

In order to assess the change of erectile function, patients completed the International Index of Erectile Function (IIEF) prior to treatment and at least 4 weeks’ post. One of the expert physicians that lead the study, Joseph Banno, MD, stated ‘I’m amazed at how well my patients are responding to PRP. It’s exciting to offer a safe modality, one without side effects, for the treatment of sexual dysfunction.’

PRP may revolutionize the way that sexual dysfunction is treated. For physicians such as Paul Perito, MD, who says ‘I’m always looking for innovative solutions for my patients and for the many physician’s I train. PRP is one of the most promising tools I’ve added in years!’ PRP will transform how conditions such as ED are treated. Research suggests as the study of this technology continues, PRP therapies may eventually be able to treat myriad of medical conditions as the benefits will continue to grow.